Visualization of Ramger Drug Coated Balloon, from side close-up.
Medical specialties  /  Vascular Surgery / Drug Eluting Therapies /  Ranger

 

 

A bold step forward.

Boston Scientific is committed to advancing science in the fight against PAD by boldly innovating with next-generation, drug-eluting technology. Backed by Level-1 Randomised Controlled Trials, our exceptional results put the power of choice in the hands of those who make it happen. Together, we can save more limbs and help more people walk without pain.

 

Ranger Drug Eluted Stent illustration with purple tip

NEXT-GENERATION TECHNOLOGY

Delivers like nothing else.

Ranger DCB is built on the physician preferred Sterling™ 0.014”/0.018” balloon platform1 with a low entry profile.
Ranger DCB Technology ›
Man sitting on porch with cane at his side, looking to the right.

BOLD CLINICAL TRIALS

Two randomised control trials.1,2
Zero doubt.

Bold is being the first company to voluntarily evaluate our Drug-Coated Balloon against another DCB in a Level-1 Randomised Controlled Trial for comparative effectiveness. Ranger™ DCB demonstrated similar primary patency as IN.PACT with half the total drug dose5 at 2-Years. And consistently demonstrated high primary patency, near 90%, at 1-Year in the RANGER II SFA & COMPARE Trials6.
Ranger DCB Clinical Trials ›

 

Clinical Highlights

 

Exceptional outcomes at 2-Years7. No matter the lesion complexity. No matter the patient.

In the RANGER II SFA RCT, Ranger demonstrated 84% K-M primary patency at 2-Years.7

RANGER II SFA Trial
Ranger DCB primary patency chart

 
Background image of surgical area and healthcare providers' hands.

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Explore Resources ›
Background image of healthcare providers' hands using medical equipment.

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Sign Up Today ›
take the fight to pad
Top